Investor Connect Podcast

The content is almost entirely a rehearsed investor pitch deck read aloud, not an interview designed to educate. A handful of data-backed claims exist (mechanism, deal comps, PRV voucher) but they are mixed with boilerplate market-size framing and no operational takeaways for a B2B operator outside pharma biotech.

“Our novel compound ATX 1209 works as a, as a modulator to the opioid receptor by suppressing the dependent signals and preserving the analgesic signals with one pill”

“The last one sold for about $200 million in December”

The competitive-positioning argument - making opioids safe rather than replacing them - is a genuinely contrarian frame in a field where every competitor compromises efficacy for safety. This single insight stands out; the rest is standard fundraising boilerplate (warfarin/Eliquis analogy, TAM framing, team slide language).

“if opioids aren't going away, why don't we just make them safe? We're the only TPP in development basically with opioid equivalent analgesia without a safety risk”

“every other approach is going after sun non opioid target that unfortunately just doesn't hit the mark in terms of pain relief. So they're all compromising efficacy for better safety. That's the approach the entire field is taking”

The presenter has legitimate operational credentials (Coherus IPO, 25 years in pharma) and the scientific co-founder has real academic standing (400+ publications, UCSF/Ohio State), but the format is a fundraising pitch rather than a knowledge-sharing session, meaning expertise is asserted rather than demonstrated through depth of discussion.

“I also was on the early team of Coheras where we went from a startup to a $200 million IPO within about four years and on to a $1.2 billion valuation”

“Wolfgang CD is the brains behind this discovery out of UCSF in Ohio State. He's a world renowned researcher with over 400 publications”

For a pitch, the evidence layer is reasonably concrete: named deal comps with floor prices, grant dollar amounts, clinical timelines, IP expiry dates, and a specific market mechanism comparison. However, the data is entirely self-selected and forward-looking projections are presented as near-certainties without independent validation.

“There's been two deals done recently in the non addictive pain space. Both of those were the floor on those was $300 million the last 12 months. One was the Tigo Biosciences and the other one was Lilly's takeout of Site 1”

“We have funded this company with about $5 million in grants plus some additional seed money”

The Q&A is negligible: one investor admits he has 'not a whole lot of questions,' another investor's competitor challenge is so vague he can't even name the company or its target, and the host contributes nothing beyond facilitation. No assumption is probed, no projection challenged, no follow-up pursued.

“I don't really have a whole lot of questions. The only concern I've got is the group up in Montreal that is developing a similar product to what you are”

“I don't know, I don't remember off the top I remember that it's um, an opioid replacement type of therapy and I don't remember that much about it”